Trial Profile

A Phase 1b/ 2a clinical trial of IMX-110 in soft tissue sarcoma

Status: Active, no longer recruiting

Phase of Trial: Phase I/II

Latest Information Update: 16 Jun 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

14 Jun 2023 According to an Immix Media Release, the company announced that it has completed its previously announced at-the market equity offering program. It has completed 5 million dollars common stock offering. It intends to use net proceeds from the ATM offering for its IMX-110 plus tislelizumab phase 1b combination clinical trial, its IMX-110 monotherapy clinical trial and general corporate purposes.
20 Dec 2022 According to Immix Biopharma media release, 16th patient has been dosed in this trial and the second patient dosed so far in December 2022. This patient has a relapsed/refractory pecoma. Trial data is expected to be released on a rolling basis beginning in Q1 2023; once dosing begins, patients undergo CT scans every 8 weeks to assess tumor response to IMX-110.
27 Jan 2022 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com